Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Corrigendum

Corrigendum to “Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicenter study of the Italian Melanoma Intergroup (IMI)” [Eur J Canc 137 (2020). Pages 30–39]

Mario Mandalà ^{a,*}, Francesca Galli ^b, Roberto Patuzzo ^c,
 Andrea Maurichi ^c, Simone Mocellin ^{d,e}, Carlo R. Rossi ^{d,e}, Eliana Rulli ^b,
 Maria Montesco ^f, Pietro Quaglini ^g, Virginia Caliendo ^h,
 Vincenzo De Giorgi ⁱ, Barbara Merelli ^a, Corrado Caracò ^j,
 Dario Piazzalunga ^k, Alice Labianca ^a, Simone Ribero ^f, Rebecca Senetta ^l,
 Andrea Gianatti ^m, Barbara Valeri ⁿ, Daniela Massi ^o, Paolo A. Ascierto ^p,
 Mario Santinami ^c, Italian Melanoma Intergroup (IMI)

^a Unit of Medical Oncology, Papa Giovanni XXIII Hospital, Bergamo, Italy

^b Methodology for Clinical Research Laboratory, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy

^c Melanoma and Sarcoma Unit, Department of Surgery, IRCCS Fondazione Istituto Nazionale dei Tumori, Milan, Italy

^d Unit of Surgery, Veneto Institute of Oncology - IOV, Italy

^e University of Padua, Italy

^f Pathological Anatomy and Histology, Veneto Institute of Oncology - IOV, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy

^g Dermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Turin, Italy

^h Department of Surgery, University of Turin Medical School, Italy

ⁱ Department of Dermatology, University of Florence, Italy

^j Istituto Nazionale Tumori IRCCS Fondazione ‘G. Pascale’, Naples, Italy

^k Unit of Surgery, Papa Giovanni XXIII Hospital, Bergamo, Italy

^l Pathology Division, ‘Città della Salute e della Scienza di Torino’ University Hospital, Turin, Italy

^m Unit of Pathology, Papa Giovanni XXIII Hospital, Bergamo, Italy

ⁿ Department of Pathology and Laboratory Medicine, IRCCS Fondazione Istituto Nazionale dei Tumori di Milano, Milan, Italy

^o Histopathology and Molecular Diagnostics, Careggi University Hospital, Florence, Italy

^p Unit Melanoma, Cancer Immunotherapy and Innovative Therapies, Istituto Nazionale Tumori IRCCS Fondazione ‘G. Pascale’, Naples, Italy

DOI of original article: <https://doi.org/10.1016/j.ejca.2020.07.001>.

* Corresponding author: Unit of Medical Oncology, Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Piazza OMS 1, 24100, Bergamo, Italy.

E-mail address: mmandala@asst-pg23.it (M. Mandalà).

The authors regret that the affiliation details are incorrect for Authors Simone Mocellin and Carlo R. Rossi. The correct affiliation details are given below.

Simone Mocellin^{d,e}

^d Unit of Surgery, Veneto Institute of Oncology - IOV

^e University of Padua, Italy

Carlo R. Rossi^{d,e}

^d Unit of Surgery, Veneto Institute of Oncology - IOV

^e University of Padua, Italy

The authors would like to apologise for any inconvenience caused.